Immune checkpoint inhibitor rechallenge in patients with immune-related myositis

Neither myositis-specific nor myasthenia gravis autoantibodies were detected.ICIs were stopped and three pulses of methylprednisolone followed by tapering doses of prednisone were given leading to complete remission within 8 weeks.Because of the lack of efficacy of the single infusion of ICI combination followed by three infusions of dacarbazine, pembrolizumab was introduced 8 months after the myositis episode.The patient presented no irAEs or myositis (table 1) but died due to melanoma progression.Despite the risk of recurrent irAEs, rechallenging ICIs after discontinuation due to previous irAEs remains critical, when considering their potential benefits in terms of survival. 5These two cases suggest that resuming ICIs can be safe in patients displaying persistent remission of ICI-related myositis.